Lapsed Aug 7, 2026 on the fee record · Medium confidence
20-year base term ends Sep 22, 2029
Why Medium: A terminal disclaimer is on file (approved) with no resolved reference, so the term may end earlier.
Second maintenance fee unpaid; grace period ended.
Held by Phio Pharmaceuticals Corp.
Filed Mar 23, 2011 as application 13/069,780 · Granted Aug 7, 2018
Base term, 20 years from filing, plus 533 days of patent term adjustment (USPTO delay)
Today
Lapsed Aug 7, 2026
2009
2031
Clock starts
Sep 22, 2009
Sep 22, 2009
No longer in force
Aug 7, 2026
Aug 7, 2026
Granted
Aug 7, 2018
Aug 7, 2018
Term would have run to
Mar 9, 2031
Mar 9, 2031
base term
patent term adjustment
after the term ends
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
533
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to Mar 9, 2031: its 20-year base term plus 533 days of term adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 22, 2009, when application PCT/US2009/005247, the earliest non-provisional in its chain, was filed (this one was filed Mar 23, 2011) | Sep 22, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +533 days, USPTO patent term adjustment record | Mar 9, 2031 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | lapsed Aug 7, 2026 | High confidence |
| Computed term end | The steps above, in order | Aug 7, 2026 | Medium confidence |
This family
| Application PCT/US2009/005247 | PCT application no patent term | no patent term |
| US 10,041,073 | this patent Aug 2026 | Aug 2026 |
| US 8,796,443 | In force no later than May 2030 | no later than May 2030 |
| US 9,175,289 | In force no later than Sep 2029 | no later than Sep 2029 |
| US 10,774,330 | In force no later than Sep 2029 | no later than Sep 2029 |
| US 10,876,119 | Lapsed on the fee record Dec 2024 | Dec 2024 |
| Application 16/934,864 | Pending not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 26, 2011 Reel 26969, frame 660 | Rxi Pharmaceuticals Corporation | RNCS, Inc. | Assignment of Assignor's Interest |
| Sep 26, 2011 Reel 26976, frame 187 | RNCS, Inc. | Tang Capital Partners, LP | Security Agreement |
| Sep 29, 2011 Reel 26988, frame 874 | RNCS, Inc. | Rxi Pharmaceuticals Corporation | Change of Name |
| May 2, 2012 Reel 28144, frame 110 | Tang Capital Partners, LP | Rxi Pharmaceuticals Corporation | Release of Security Interest |
| Jun 19, 2013 Reel 30643, frame 1 | Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Cardia, James | Rxi Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Dec 7, 2018 Reel 48380, frame 9 | Rxi Pharmaceuticals Corporation | Phio Pharmaceuticals Corp. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Note
The 533 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Aug 7, 2026. We will not guess the cap.
Citations
117
later US patents cite this one
That is top 5% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.